The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, named director Kirk Perry as interim chief executive ...

Kenvue (KUVE) has named Kirk Perry, a current director, as its interim CEO, effective immediately. Concurrently, Thibaut ...

With activist investor Starboard Value holding a seat on Kenvue’s board of directors, the consumer healthcare company is ...

(RTTNews) - While reporting financial results for the second quarter on Tuesday, Kenvue, Inc. (KVUE) reaffirmed its adjusted earnings and net sales growth guidance for the full-year 2024.

Additionally, Herzog recognizes that the performance of Kenvue’s various categories is subject to seasonality, which may impact the timing of their financial results.

The company is working to reduce tariffs’ financial impact through several mitigation actions. On Thursday, Kenvue appointed Amit Banati as the company’s CFO, effective May 12, 2025. Mr.

Separately, Kenvue announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will succeed Paul Ruh, who will remain with the Company for a brief ...

Kenvue recently held its first earnings call as a standalone public company. While financial results are limited, the stock trades for a noticeable discount to its peers. Spinoffs tend to be well ...

Financial Outlook and Projections Analysts project Kenvue's earnings per share (EPS) for the upcoming fiscal year to be around $1.15, with expectations of modest growth.

Editor’s Note: Self care segment revenue growth updated Consumer health company Kenvue Inc. (NYSE:KVUE) on Thursday reported first-quarter 2025 sales of $3.74 billion, beating the consensus of ...